Key Highlights

  • Shares trading down 8.39% pre-market, losing $0.12 to reach $1.31
  • Move extends Tuesday's 6.54% regular-session decline
  • Q2 2026 Revenue increased 17% year-over-year to approximately $2.2 million
  • Net income of $0.9 million, compared to a net loss of $3.6 million a year earlier, aided by a $2.5 million gain on remeasurement tied to the Birmingham clinic acquisition
  • Clinic platform was profitable on an Adjusted EBITDA basis before corporate expenses, generating approximately $333,000 in the quarter
  • Cash totaled $3.7 million as of June 30, 2026, up from $2.1 million at the end of 2025

Shares Extend Decline Despite Return to Profitability

INVO Fertility (NASDAQ:IVF) shares are falling further in pre-market trading Wednesday, down 8.39% to $1.31, extending Tuesday's 6.54% regular-session decline even after the company reported a return to Net Income in its second quarter. Revenue increased 17% year-over-year to approximately $2.2 million, and the company posted net income of $0.9 million, compared to a net loss of $3.6 million a year earlier, aided by a $2.5 million gain on remeasurement tied to its Birmingham clinic acquisition.

INVO Fertility is a Sarasota, Florida-based healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies. The company operates through its Fertility Clinic Services, INVOcell Device, and Therapeutics segments, with its principal commercial strategy centered on building, acquiring, and operating fertility clinics, including its proprietary INVO Centers that offer the intravaginal culture procedure enabled by its flagship INVOcell medical device, a proprietary technology allowing fertilization and early embryo development to occur in vivo within a woman's body.

Clinic Platform Turns Profitable Despite Overall Losses

The clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses, generating approximately $333,000 during the quarter, up from approximately $164,000 in the first quarter of 2026. "The second quarter continued the progress we demonstrated in the first quarter and provided further validation of our strategy," said Steve Shum, Chief Executive Officer of INVO Fertility. In June 2026, the company acquired the remaining ownership interests in its Birmingham, Alabama fertility clinic, converting it from a joint venture into a wholly owned subsidiary.

Despite the clinic-level profitability and revenue growth, consolidated Adjusted EBITDA remained negative at approximately $1.0 million for the quarter, compared to negative $0.6 million a year earlier, reflecting continued corporate overhead and public company costs. Cash totaled $3.7 million as of June 30, 2026, up from $2.1 million at the end of 2025, as the company continues to evaluate a pipeline of additional U.S.-based, profitable fertility clinic Acquisition targets.

Conclusion

INVO Fertility's continued pre-market decline, despite a return to net income and clinic-level profitability, suggests investors remain focused on the company's still-negative consolidated Adjusted EBITDA and small overall scale. With a growing pipeline of acquisition targets and demonstrated clinic-level Earnings power, the stock's next moves will likely hinge on whether the company can scale its platform enough to offset corporate overhead costs.